These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7006709)

  • 1. Timed sequential chemotherapy of cytoxan-refractory multiple myeloma with cytoxan and adriamycin based on induced tumor proliferation.
    Karp JE; Humphrey RL; Burke PJ
    Blood; 1981 Mar; 57(3):468-75. PubMed ID: 7006709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of serum stimulation and plasma cell proliferation during chemotherapy of multiple myeloma.
    Karp JE; Burke PJ; Humphrey RL
    Blood; 1977 Jun; 49(6):925-34. PubMed ID: 861376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of proliferative and clonogenic tumor cells in multiple myeloma.
    Karp JE; Burke PJ; Saylor PL; Humphrey RL
    Cancer Res; 1984 Sep; 44(9):4197-200. PubMed ID: 6744329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma.
    Lenhard RE; Kalish LA; Oken MM; Ettinger DS; Glick J
    Cancer; 1994 Apr; 73(8):2113-8. PubMed ID: 8156516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recruitment of quiescent tumor by humoral stimulatory activity: requirements for successful chemotherapy.
    Burke PJ; Karp JE; Vaughan WP; Sanford PL
    Blood Cells; 1982; 8(3):519-33. PubMed ID: 7159763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.
    Bell JB; Millar BC; Montes-Borinaga A; Joffe JK; Cunningham D; Mansi J; Treleaven J; Viner C; McElwain TJ
    Hematol Oncol; 1990; 8(6):347-53. PubMed ID: 2286358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adriamycin and Cytoxan in the treatment of inoperable lung cancer.
    Hoeltgen TM; MacIntyre JM; Perlia CP; Lagakos SW; Stolbach LL; Bennett JM
    Cancer; 1983 Jun; 51(11):2005-12. PubMed ID: 6301671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoclastome-like giant cell thyroid carcinoma controlled by intensive radiation and adriamycin, in a patient with meningioma and multiple myeloma treated by radiation and cytoxan.
    Vizel-Schwartz M
    J Surg Oncol; 1981; 17(1):57-61. PubMed ID: 7230831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisone pulse therapy for refractory myeloma.
    Alexanian R; Yap BS; Bodey GP
    Blood; 1983 Sep; 62(3):572-7. PubMed ID: 6882916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine.
    Hofmann V; Salmon SE; Durie BG
    Blood; 1981 Sep; 58(3):471-6. PubMed ID: 7259835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation.
    Tannock I
    Cancer Res; 1982 Dec; 42(12):4921-6. PubMed ID: 7139596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.
    Ballestrero A; Ferrando F; Miglino M; Clavio M; Gonella R; Garuti A; Grasso R; Ghio R; Balleari E; Gobbi M; Patrone F
    Eur J Haematol; 2002 Feb; 68(2):101-6. PubMed ID: 12038448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.
    Alahmadi M; Masih-Khan E; Atenafu EG; Chen C; Kukreti V; Tiedemann R; Trudel S; Reece DE
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e195-e203. PubMed ID: 30723035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.
    Alberts DS; Salmon SE
    Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive sequential therapy for VAD-resistant multiple myeloma.
    Dimopoulos MA; Weber DM; Hester J; Delasalle K; Champlin R; Alexanian R
    Leuk Lymphoma; 1994 May; 13(5-6):479-84. PubMed ID: 7915163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
    Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ; Karp JE; Vaughan WP
    J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.